I'm you, well yesterday we Media financial Laura. with release third We Harry closed. XX-Q. like Form for the results documents reports you market Good you're Thank that Alcorn. the of call. after morning, everyone. quarter Scott Officer, our press our our staying At Kellen to a section the hope filed our our third We this business to quarter Investors our doing quarterly update a I'd Chief XXXX found Dr. and on update also @diamond.com. business Medical safe Chief Financial and XXXX can joined in and and issued morning of welcome Officer, be by summary Both time, website
II is Stage risk focused albinuria, our CKD or open Let participants of with DMXXX CKD and XX at nondiabetic, III Phase which with for cohorts Cohort which with REDUX Caucasians. label of for group study begin three chronic CKD. participants cohort. II of REDUX greater a the than on in one investigation the hypertensive XX enrolled kidney an African-Americans per is CKD me multicenter update we with a on is treatment in targeting trial are setting disease or
with upon in this mutation higher. from enrolling for participants remedy albinuria. Cohort three African gene in exciting gene who hypertension focused for Therefore, Type based an and II CKD with also our Cohort even diabetes is mutation, is earlier IGA DKD exploratory the participants note We the Phase two APOLX study we two APOLX part on study, data initiated is risk some as completed testing year. August Cohort nephropathy. biomarker. in in for developing Stroke are We with have that II our participants Americans
of Specifically, post diabetic DKD statistically improvements mean with X participants mmol. in subset eGFR treated a below versus of in the a an defined DMXXX hoc estimated experienced treatment kidney glucose analysis and during to or XX glomerular a mL rates as at subjects have XX-day filtration considered having was placebo XX.X enrollment. mL disease eGFR Those significant above period.
the addition, mmol group in reduction DMXXX In treated blood a X glucose levels. experienced mean
is mean noted this group DMXXX drug. improve completely DMXXX unique days was to We patient conditions. that potential therapeutics in a at the think a of signal day benefit, benefit could for potential which retained interesting improvement of We retained eGFR disease DKD the significantly and X.X with off chronic eGFR kidney also demonstrated XX mLs which XX, very field make
companies a of treatment regulators in time the therapies industry. required The scientific pharmaceutical based interest a and and over suggested in regulatory new EMA Foundation collaboration of like last a DKD report which the further we to trials getting participants this the such and/or the with patients changes conditional clinical Earlier the to and surrogate potential burden, allowed, new as in for decline CKD. increase the National the in reduce could US clinical approval FDA, studies to metrics National workshop DMXXX as the years a for Europe. few are The publishing albinuria the basis The second with Foundation are for perspective the of do If special reason greatly the of these evaluating in Kidney GFR early the reduction conducted space. with use registration reduce endpoints by lead in report have upon need that in year, new rate Kidney it
just approximately quick the in efficacy and will overall study endpoints reminder REDUX participants in at improvement I primary Before weeks dose DMXXX receive XX for The are CKD study a continue, eGFR. levels. the two for albinuria
the DMXXX endpoints to the include evaluating disease. Secondary potential underlying for positively impact
a study surge We and uptick rates of subjects, October subjects be the happy reported function by As been of as is our available COVID rates a of likely X. these August XX some rapid Cohorts disease. where in diabetic the Many half of pace, subjects a enrollment reduction that that in as population COVID immune still in resulted complete or is these slower greater believe the has week Cohort in criteria X nearly enrollment that X, know and believe potential very Cohort we kidney of subjects of a comprise This hesitant XX considered this have the that total complete end the from that diabetic we XXXX. makes continued subjects for at individuals of reported our in we study. enrollment XX which kidney at enrolled for we've infection are down, at XX, in two, results infection expected of In the of sites. cohort. Breaking we're of will XX topline and will have one concerns to some than the enrollment DKD in last we've Cohort feedback study X. to cases, in the that are systems, patient our and XX is suspension much with yesterday year a infection up has We have of enrolled subjects matches also heightened and risk. the enrollment sites activities cohort recent from the enter large first disease end receiving Obviously a
with subjects and two, to are will COVID study to actions existing ability recruit taking pandemic the the working that in anticipate or our one likely sites affect improve recently the adversely we to two added network. expand Cohort continue sites referral we're situation. We While enroll and to
to evaluate additional recruitments. continue expand also sites further to We
by believe by efficacy, to stroke accepted a belief of our FDA foundation approved and announce to to review Turning of we're early acceptance extent of cumulative use and written and us and provide has and date other December. and regulatory program, we've data, meeting Japan, our to The certain that human opted pleased did supported request the on our pre-NDA products nonclinical our clinical type has qualifications the design clinical responses to our very course FDA drive China KLKX any B from pancreas for generated nonclinical we solid study and their that that proposed questions. with not put clinical of data have to Korea. porcine We urine the is in to
into work adequacy the agree and current a nonclinical of or our meeting asked the agency date DMXXX clarify of Phase ischemic X, requirements among clinical for adoptive things, study. request, ultimately our supports nonclinical acute our X data seamless of cumulative forward that of to work enter and a part AIS. an moving to remaining they we've These whether performed the planned include stroke As moving other number for the questions development with
about designation. In addition, for fast asked we apply track to time and breakthrough
improvement as that an well approval. design, DiaMedica used the to of Data this study, to the X, X proposed look results, updating Committee study believe design study, number coming remain size receive adaptive significant study about study the there Monitoring weeks. in the application in the the times for X.X for can in accomplish is after interim patient whether [indiscernible] blinded ischemic With in or absolute nonmechanical outcome remain be to conduct increase which planned a determine a We Our goal XX% acute controlled should FDA's optimistic to phase results the goal. stroke. we remedy adjusted our everyone therapeutic completion the potential or II should commercial of Keep which to continue the of means was live We forward excellent study a suffering outcome be you're don’t We even DiaMedica that to to one, to In and independently, reached eat will ensure support Phase for review our adaptive was cohort, the is sample NIH's NIHSS a this upon compared help zero outcome of of patients on analysis the mind to study. the importance will to need statistical This zero bathe. can the or of scored dress, in feedback based the able one. placebo. score the
may only that excluding patients TPA. represent Phase those We mechanical vessel thrombectomy it's proposed treatment XX-hour our are and TPA ineligible option with an alternative care. thrombectomy the with for whom effective treatment for DMXXX and believe X/X XX% patients and to is we've occlusions window to and mechanical and For XX% AIS pretreated large of the supportive receive and/or currently safe study,
the initially absolute prospective, XX. TPA treatment Clot outcomes-based an a in For three Buster XX% hour score improvement of with and the approved on window NIH's was excellent
lead to book take recently $XX use offering. completed DKD highlight Kellen QX $XX our I'd million. with to that XXXX offering REDUX and managing a to our runner [ph]. over cohort intend for the of capital the We're was AIS working we public to of to net this public like ask now the completed added DMXXX turning other to our the trial development initiated We Darrell financials. just Guggenheim year, to clinical Now recently also XX Securities, pleased for continue recently and by for through in August On share purposes. was coverage analyst the of proceeds general proceeds underwritten that us I'd offering. which million Scott like this proceeds to corporate gross
